Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,520.00    0.00 (0.00%)
Bid:
1,100.00
Ask:
2,200.00
Spread: 1,100.00 (100.00%)
Market Cap: £3.20b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20209:31 amRNSTotal Voting Rights
22nd May 20207:00 amRNSHikma receives FDA approval for generic Vascepa®
20th May 20203:42 pmRNSDirector/PDMR Shareholding
13th May 20201:28 pmRNSDirector/PDMR Shareholding
1st May 202011:30 amRNSTotal Voting Rights
30th Apr 202012:00 pmRNSResult of AGM
30th Apr 20207:00 amRNSDirectorate Change
30th Apr 20207:00 amRNSTrading Statement
16th Apr 20203:07 pmRNSDirector/PDMR Shareholding
14th Apr 20202:30 pmRNSBlock listing Interim Review
2nd Apr 20207:00 amRNSAGM Update
31st Mar 20207:00 amRNSHikma's favourable ruling in generic Vascepa®
24th Mar 202010:52 amRNSDirector/PDMR Shareholding
19th Mar 202012:00 pmRNSAnnual Financial Report
28th Feb 202012:27 pmRNSDirector/PDMR Shareholding
28th Feb 202012:26 pmRNSDirector/PDMR Shareholding
28th Feb 202012:23 pmRNSDirector/PDMR Shareholding
27th Feb 20204:40 pmRNSDirector/PDMR Shareholding
27th Feb 20204:35 pmRNSBoard Committee Changes
27th Feb 20207:05 amRNSHikma enters agreement to commercialise Ryaltris™
27th Feb 20207:00 amRNSFinal Results
4th Feb 20202:06 pmRNSTotal Voting Rights
4th Feb 20209:07 amRNSNotice of Results
15th Jan 20209:46 amRNSDirector/PDMR Shareholding
15th Jan 20209:44 amRNSDirector/PDMR Shareholding
9th Jan 20208:00 amRNSHikma announces agreement with Arecor
2nd Jan 202010:56 amRNSTotal Voting Rights
10th Dec 201912:06 pmRNSCivica Rx and Hikma announce shipment of medicines
2nd Dec 20195:12 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSHikma completes FDA response for generic Advair®
21st Nov 20192:47 pmRNSDirector/PDMR Shareholding
8th Nov 201911:17 amRNSBlock Listing Application
7th Nov 20197:00 amRNSTrading Statement
5th Nov 20199:34 amRNSTotal Voting Rights
4th Oct 20191:36 pmRNSHolding(s) in Company
1st Oct 20193:15 pmRNSBlock listing Interim Review
1st Oct 20193:02 pmRNSTotal Voting Rights
17th Sep 20199:00 amRNSHikma launches prefilled syringes in the US
10th Sep 201910:05 amRNSNotice of Accession of Guarantor
6th Sep 20193:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20195:13 pmRNSTotal Voting Rights
13th Aug 201910:20 amRNSDirector/PDMR Shareholding
9th Aug 20199:00 amRNSHikma expands nasal spray capabilities
9th Aug 20197:00 amRNSHalf-year Report
1st Aug 20193:04 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSHikma and Richter sign agreement for cariprazine
23rd Jul 20199:00 amRNSHikma and Civica Rx sign long-term agreement
8th Jul 20199:00 amRNSNotice of Results
2nd Jul 20195:54 pmRNSTotal Voting Rights
3rd Jun 20194:29 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.